Abbott Laboratoriesvs.Bio-Rad Laboratories
ABT vs BIO · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 18× larger than Bio-Rad Laboratories by market cap; Abbott Laboratories trades at the lower P/E (31.8 vs 44.1); year to date, Bio-Rad Laboratories leads (+18.9% vs −21.4%).
Side by side
| ABT | BIO | |
|---|---|---|
| Market cap | $172B | $9.8B |
| Price | $99.60 | $366.16 |
| Today | +1.1% | +1.6% |
| Return YTD | −21.4% | +18.9% |
| Return 1Y | −26.6% | +19.0% |
| Since June 26, 2026 | +5.8% | +21.7% |
| P/E | 31.8 | 44.1 |
| P/S | 3.7 | 3.8 |
| P/B | 3.4 | 1.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Abbott LaboratoriesABT
In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.
Full ABT profile →Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →More ABT & BIO comparisons
Other head-to-heads in the Diagnostics segment.